Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.
The FDA asked, and Eli Lilly and Company delivered. The company now hopes to secure an additional approval for orforglipron/Foundayo that covers the treatment of type 2 diabetes.
Landiolol, sold under the brand name Rapiblyk, is only meant to be administered in a hospital setting. It was initially approved for adult patients in 2024.